<DOC>
	<DOC>NCT00529451</DOC>
	<brief_summary>This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.</brief_summary>
	<brief_title>Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Patients must have msDBP â‰¥ 90 mmHg and &lt; 110 mmHg at the visit immediately prior to Visit 3 Patients must have msDBP &gt;OR= 95 mmHg and &lt; 110 mmHg at Visit 3 Patients must have an absolute difference of &lt; or =10 mmHg in their mean sitting diastolic blood pressure (msDBP) from Visit 2 to Visit 3 Severe hypertension (grade 3 WHO classification; msDBP &gt;or= 110 mmHg and/or msSBP &gt;or = 180 mmHg). History or evidence of a secondary form of hypertension. History of transient ischemic cerebral attack within 12 months of visit 1. Current angina pectoris requiring pharmacological therapy (other than those patients on a stable dose of oral or topical nitrates) Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) &gt; 8% at Visit 1. Known or suspected contraindications to the study medications, including history of allergy to ramipril or other ACE Inhibitors. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hypertension, Aliskiren, Ramipril</keyword>
</DOC>